Connect Biopharma Holdings Ltd. presented its corporate presentation, highlighting significant advancements in its drug development program. The company is focused on progressing its anti-interleukin-4-receptor alpha (IL-4Rα) treatment, Rademikibart, targeting eosinophilic-driven respiratory diseases such as asthma and COPD. The presentation outlined the initiation of Phase 2 studies for acute COPD and asthma exacerbations in the U.S., with data expected in the first half of 2026. Rademikibart is noted for its potential commercial appeal, especially due to its acute exacerbation indications, which differentiate it from other biologics. The company has global development and commercialization rights outside of greater China and anticipates significant market opportunities with projected worldwide peak sales. You can access the full presentation through the link below.